🇺🇸 FDA
Patent

US 12186378

Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonists

granted A61KA61K31/165A61K31/198

Quick answer

US patent 12186378 (Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonists) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/165, A61K31/198, A61K38/51, A61P